U
PCRX icon

UBS’s Pacira BioSciences PCRX Stock Holding History

UBS’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$465K Buy
4,800
+200
+4% +$19.5K ﹤0.01% 4349
2014
Q2 		$423K Buy
4,600
+4,200
+1,050% +$320K ﹤0.01% 4396
2014
Q1 		$28K Sell
400
-1,100
-73% -$74.8K ﹤0.01% 7640
2013
Q4 		$86K Sell
1,500
-7,500
-83% -$394K ﹤0.01% 6253
2013
Q3 		$433K Buy
9,000
+8,800
+4,400% +$321K ﹤0.01% 4297
2013
Q2 		$6K Buy
+200
New +$5.79K ﹤0.01% 9127

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's PCRX Position: Q3 2014 in Review

UBS reduced its Pacira BioSciences (PCRX) stake by 23% in Q3 2014, selling an estimated $562K and leaving 19,624 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

UBS first reported a position in PCRX in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.33M in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

  • UBS held 19,624 shares of Pacira BioSciences worth $1.9M as of Q3 2014.
  • UBS sold 5,776 Pacira BioSciences shares in Q3 2014, an estimated $562K.
  • Pacira BioSciences made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2956 holding.
  • UBS first reported a position in Pacira BioSciences in Q2 2013 and has held it in 6 quarters since.
  • UBS's Pacira BioSciences position peaked at $2.33M in Q2 2014.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.